Found: 102
Select item for more details and to access through your institution.
Guselkumab demonstrates long-term efficacy and maintenance of treatment response postwithdrawal in systemic treatment-naïve patients and nonresponders to fumaric acid esters: results from parts II and III of a randomized active-comparator-controlled phase IIIb trial (POLARIS)
- Published in:
- British Journal of Dermatology, 2024, v. 191, n. 1, p. 36, doi. 10.1093/bjd/ljad523
- By:
- Publication type:
- Article
SARS‐CoV‐2 infection among psoriasis patients in Germany: Data from the German registries PsoBest and CoronaBest.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 7, p. 965, doi. 10.1111/ddg.15433
- By:
- Publication type:
- Article
SARS‐CoV‐2‐Infektionen bei Patienten mit Psoriasis in Deutschland: Daten aus den deutschen Registern PsoBest und CoronaBest.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2024, v. 22, n. 7, p. 965, doi. 10.1111/ddg.15433_g
- By:
- Publication type:
- Article
Risk of cardiovascular disorders in hidradenitis suppurativa patients: a large‐scale, propensity‐matched global retrospective cohort study.
- Published in:
- International Journal of Dermatology, 2024, v. 63, n. 6, p. 799, doi. 10.1111/ijd.17186
- By:
- Publication type:
- Article
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
- Published in:
- American Journal of Clinical Dermatology, 2024, v. 25, n. 3, p. 485, doi. 10.1007/s40257-024-00853-4
- By:
- Publication type:
- Article
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 5, p. 668, doi. 10.1093/bjd/ljae014
- By:
- Publication type:
- Article
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials.
- Published in:
- British Journal of Dermatology, 2024, v. 190, n. 4, p. 477, doi. 10.1093/bjd/ljad429
- By:
- Publication type:
- Article
Etanercept in Axial Spondyloarthritis, Psoriatic Arthritis, and Plaque Psoriasis: Real-World Outcome Data from German Non-interventional Study ADEQUATE.
- Published in:
- Rheumatology & Therapy, 2024, v. 11, n. 2, p. 331, doi. 10.1007/s40744-023-00633-2
- By:
- Publication type:
- Article
Chronische Entzündungserkrankungen in Deutschland: Eine Querschnittanalyse über Begleiterkrankungen und Arzneimitteleinsatz.
- Published in:
- Zeitschrift für Rheumatologie, 2024, v. 83, n. 3, p. 200, doi. 10.1007/s00393-022-01306-1
- By:
- Publication type:
- Article
Response Types and Factors Associated with Response Types to Biologic Therapies in Patients with Moderate-to-Severe Plaque Psoriasis from Two Randomized Clinical Trials.
- Published in:
- Dermatology & Therapy, 2024, v. 14, n. 3, p. 745, doi. 10.1007/s13555-024-01123-1
- By:
- Publication type:
- Article
A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany.
- Published in:
- British Journal of Dermatology, 2024, v. 190, p. ii53, doi. 10.1093/bjd/ljad498.055
- By:
- Publication type:
- Article
Are interleukin 17 and interleukin 23 inhibitors associated with malignancies?—Insights from an international population‐based study.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2024, v. 38, n. 2, p. 315, doi. 10.1111/jdv.19520
- By:
- Publication type:
- Article
Efficacy and Safety of Candidate Biosimilar CT-P43 Versus Originator Ustekinumab in Moderate to Severe Plaque Psoriasis: 28-Week Results of a Randomised, Active-Controlled, Double-Blind, Phase III Study.
- Published in:
- BioDrugs, 2024, v. 38, n. 1, p. 121, doi. 10.1007/s40259-023-00630-5
- By:
- Publication type:
- Article
Spesolimab for the Treatment of Generalized Pustular Psoriasis.
- Published in:
- Drugs, 2024, v. 84, n. 1, p. 45, doi. 10.1007/s40265-023-01988-0
- By:
- Publication type:
- Article
Upadacitinib treatment withdrawal and retreatment in patients with moderate‐to‐severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 12, p. 2558, doi. 10.1111/jdv.19391
- By:
- Publication type:
- Article
Correction: Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.
- Published in:
- 2023
- By:
- Publication type:
- Correction Notice
A life for autoimmune blistering diseases: in memoriam Detlef Zillikens.
- Published in:
- Frontiers in Immunology, 2023, p. 1, doi. 10.3389/fimmu.2023.1291590
- By:
- Publication type:
- Article
A Phase IIIb, Multicentre, Interventional, Randomised, Placebo-Controlled Clinical Trial Investigating the Efficacy and Safety of Guselkumab for the Treatment of Nonpustular Palmoplantar Psoriasis (G-PLUS).
- Published in:
- Dermatologic Therapy, 2023, p. 1, doi. 10.1155/2023/9967747
- By:
- Publication type:
- Article
Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2621, doi. 10.1007/s13555-023-00997-x
- By:
- Publication type:
- Article
Dupilumab Safety and Efficacy in a Phase III Open-Label Extension Trial in Children 6–11 Years of Age with Severe Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 11, p. 2697, doi. 10.1007/s13555-023-01016-9
- By:
- Publication type:
- Article
Charakterisierung von Patienten mit Psoriasisarthritis in der dermatologischen und rheumatologischen Versorgung: Analyse von zwei Registern: Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: analysis of two registries
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2023, v. 21, n. 10, p. 1170, doi. 10.1111/ddg.15178_g
- By:
- Publication type:
- Article
Characterization of patients with psoriatic arthritis in dermatologic and rheumatologic care: analysis of two registries.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2023, v. 21, n. 10, p. 1170, doi. 10.1111/ddg.15178
- By:
- Publication type:
- Article
No impact of disease duration on response to tildrakizumab treatment among patients with moderate‐to‐severe plaque psoriasis: Post hoc analyses from two phase 3 (reSURFACE 1 and reSURFACE 2) and one phase 4 (TRIBUTE) studies.
- Published in:
- Skin Health & Disease, 2023, v. 3, n. 5, p. 1, doi. 10.1002/ski2.263
- By:
- Publication type:
- Article
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 595, doi. 10.1007/s40257-023-00792-6
- By:
- Publication type:
- Article
Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
- Published in:
- American Journal of Clinical Dermatology, 2023, v. 24, n. 4, p. 609, doi. 10.1007/s40257-023-00785-5
- By:
- Publication type:
- Article
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 42, doi. 10.1093/bjd/ljad115
- By:
- Publication type:
- Article
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
- Published in:
- British Journal of Dermatology, 2023, v. 189, n. 1, p. 132, doi. 10.1093/bjd/ljad081
- By:
- Publication type:
- Article
SARS‐CoV‐2 vaccination status and adverse events among patients with psoriasis—Data from the German Registries PsoBest and CoronaBest.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 7, p. e831, doi. 10.1111/jdv.19039
- By:
- Publication type:
- Article
373 Safety of lebrikizumab in adults and adolescents with moderate-to-severe atopic dermatitis: data from eight trials.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.004
- By:
- Publication type:
- Article
418 A global, observational, cohort study of patients with atopic dermatitis to evaluate tralokinumab real-world clinical use (TRACE): baseline characteristics from the first 100 patients in Germany.
- Published in:
- British Journal of Dermatology, 2023, v. 188, p. 1, doi. 10.1093/bjd/ljad162.038
- By:
- Publication type:
- Article
Comparison of different skin care regimens in patients with moderate to severe atopic dermatitis receiving systemic treatment: A randomized controlled trial.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, p. 18, doi. 10.1111/jdv.18949
- By:
- Publication type:
- Article
Dupilumab in Inflammatory Skin Diseases: A Systematic Review.
- Published in:
- Biomolecules (2218-273X), 2023, v. 13, n. 4, p. 634, doi. 10.3390/biom13040634
- By:
- Publication type:
- Article
Long-term stability of PASI <3 response to tildrakizumab: Pooled analyses from reSURFACE 1 and reSURFACE 2 phase 3 trials through 5years.
- Published in:
- Journal of the European Academy of Dermatology & Venereology, 2023, v. 37, n. 4, p. e501, doi. 10.1111/jdv.18783
- By:
- Publication type:
- Article
Dupilumab Demonstrates Rapid Onset of Action in Improving Signs, Symptoms and Quality of Life in Adults with Atopic Dermatitis.
- Published in:
- Dermatology & Therapy, 2023, v. 13, n. 3, p. 803, doi. 10.1007/s13555-023-00894-3
- By:
- Publication type:
- Article
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
- Published in:
- British Journal of Dermatology, 2023, v. 188, n. 1, p. 22, doi. 10.1093/bjd/ljac021
- By:
- Publication type:
- Article
Efficacy of the Digital Therapeutic sinCephalea in the prophylaxis of migraine in patients with episodic migraine: study protocol for a digital, randomized, open-label, standard treatment controlled trial.
- Published in:
- Trials, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s13063-022-06933-2
- By:
- Publication type:
- Article
Phase 1 and 2 Randomized Clinical Studies Determine Lack of Efficacy for Anti-IL-17C Antibody MOR106 in Moderate–Severe Atopic Dermatitis.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 23, p. 7244, doi. 10.3390/jcm11237244
- By:
- Publication type:
- Article
Psoriasis Management Challenges Regarding Difficult-to-Treat Areas: Therapeutic Decision and Effectiveness.
- Published in:
- Life (2075-1729), 2022, v. 12, n. 12, p. 2050, doi. 10.3390/life12122050
- By:
- Publication type:
- Article
Efficacy of Tildrakizumab Across Different Body Weights in Moderate-to-Severe Psoriasis Over 5 Years: Pooled Analyses from the reSURFACE Pivotal Studies.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 10, p. 2325, doi. 10.1007/s13555-022-00793-z
- By:
- Publication type:
- Article
Paradoxical improvement of life quality in the COVID-19 era in psoriasis patients.
- Published in:
- PLoS ONE, 2022, v. 17, n. 9, p. 1, doi. 10.1371/journal.pone.0275293
- By:
- Publication type:
- Article
Dupilumab Treatment of Atopic Dermatitis in Routine Clinical Care: Baseline Characteristics of Patients in the PROLEAD Prospective, Observational Study.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 9, p. 2145, doi. 10.1007/s13555-022-00791-1
- By:
- Publication type:
- Article
Treatment Patterns and Healthcare Resource Utilization Among Patients with Atopic Dermatitis: A Retrospective Cohort Study Using German Health Claims Data.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 8, p. 1925, doi. 10.1007/s13555-022-00773-3
- By:
- Publication type:
- Article
A Digital Therapeutic Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Real World Data from Two Prospective Studies.
- Published in:
- Nutrients, 2022, v. 14, n. 14, p. N.PAG, doi. 10.3390/nu14142927
- By:
- Publication type:
- Article
Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Generalized pustular psoriasis: overview of the status quo and results of a panel discussion.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 6, p. 753, doi. 10.1111/ddg.14764
- By:
- Publication type:
- Article
Generalisierte pustulöse Psoriasis: Überblick zum Status quo und Ergebnisse einer Diskussionsrunde.
- Published in:
- Journal der Deutschen Dermatologischen Gesellschaft, 2022, v. 20, n. 6, p. 753, doi. 10.1111/ddg.14764_g
- By:
- Publication type:
- Article
Effectiveness of Etanercept in Rheumatoid Arthritis: Real-World Data from the German Non-interventional Study ADEQUATE with Focus on Treat-to-Target and Patient-Reported Outcomes.
- Published in:
- Rheumatology & Therapy, 2022, v. 9, n. 2, p. 621, doi. 10.1007/s40744-021-00418-5
- By:
- Publication type:
- Article
A Digital Health Application Allowing a Personalized Low-Glycemic Nutrition for the Prophylaxis of Migraine: Proof-of-Concept Data from a Retrospective Cohort Study.
- Published in:
- Journal of Clinical Medicine, 2022, v. 11, n. 4, p. N.PAG, doi. 10.3390/jcm11041117
- By:
- Publication type:
- Article
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.
- Published in:
- Dermatology & Therapy, 2022, v. 12, n. 2, p. 495, doi. 10.1007/s13555-021-00649-y
- By:
- Publication type:
- Article